TY - JOUR
T1 - Darbepoetin alpha for the treatment of anaemia in low-intermediate risk myelodysplastic syndromes.
AU - Musto, Pellegrino
AU - Lanza, Francesco
AU - Balleari, Enrico
AU - Falcone, Antonietta
AU - Sanpaolo, Grazia
AU - Bodenizza, Carlo
AU - Scalzulli, Potito Rosario
AU - La Sala, Antonio
AU - Campioni, Diana
AU - Ghio, Riccardo
AU - Cascavilla, Nicola
AU - Carella, Angelo Michele
N1 - Keywords: Aged; Anemia; Erythrocyte Count; Erythropoietin; Female; Follow-Up Studies; Humans; Male; Middle Aged; Multivariate Analysis; Myelodysplastic Syndromes; Pilot Projects
PY - 2005
Y1 - 2005
N2 - Thirty-seven anaemic subjects with low-to-intermediate risk myelodysplastic syndrome (MDS) received the highly glycosylated, long-acting erythropoiesis-stimulating molecule darbepoetin-alpha (DPO) at the single, weekly dose of 150 microg s.c. for at least 12 weeks. Fifteen patients (40.5%) achieved an erythroid response (13 major and two minor improvements, respectively, according to International Working Group criteria). Such results are currently maintained after 7-22 months in 13 of the responders, one of whom required iron substitutive therapy during the treatment. One patient relapsed after 4 months. Another responder died after 5 months because of causes unrelated to the treatment. No relevant side-effects were recorded. At multivariate analysis, significant predictive factors of response were baseline serum levels of endogenous erythropoietin <100 IU/l, absent or limited transfusional needs, no excess of blasts and hypoplastic bone marrow. This study suggests that DPO, at the dose and schedule used, can be safely given in low-intermediate risk MDS and may be effective in a significant proportion of these patients.
AB - Thirty-seven anaemic subjects with low-to-intermediate risk myelodysplastic syndrome (MDS) received the highly glycosylated, long-acting erythropoiesis-stimulating molecule darbepoetin-alpha (DPO) at the single, weekly dose of 150 microg s.c. for at least 12 weeks. Fifteen patients (40.5%) achieved an erythroid response (13 major and two minor improvements, respectively, according to International Working Group criteria). Such results are currently maintained after 7-22 months in 13 of the responders, one of whom required iron substitutive therapy during the treatment. One patient relapsed after 4 months. Another responder died after 5 months because of causes unrelated to the treatment. No relevant side-effects were recorded. At multivariate analysis, significant predictive factors of response were baseline serum levels of endogenous erythropoietin <100 IU/l, absent or limited transfusional needs, no excess of blasts and hypoplastic bone marrow. This study suggests that DPO, at the dose and schedule used, can be safely given in low-intermediate risk MDS and may be effective in a significant proportion of these patients.
U2 - 10.1111/j.1365-2141.2004.05288.x
DO - 10.1111/j.1365-2141.2004.05288.x
M3 - Journal article
C2 - 15638854
SN - 0963-1860
VL - 128
SP - 204
EP - 209
JO - British Journal of Haematology, Supplement
JF - British Journal of Haematology, Supplement
IS - 2
ER -